Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform [Yahoo! Finance]
Xencor, Inc. (XNCR)
Last xencor, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xencor.com/investor-relations
Company Research
Source: Yahoo! Finance
and Trademark Office (USPTO) patent grant for independently developed RenLite ® fully human common light chain mouse platform. RenLite mice, developed using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE TM ) technology, feature the in situ replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, thereby significantly reducing the complexity of the CMC process. The molecular structures of these bispecific antibodies resemble monoclonal antibodies, exhibiting favorable physicochemical properties. Leveraging RenLite and RenLite KO mice, Biocytogen has generated a library of antibodies targeting over 200 TAA targets, enabling the rapid development of bispecific antibody and bispecific antibody
Show less
Read more
Impact Snapshot
Event Time:
XNCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XNCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XNCR alerts
High impacting Xencor, Inc. news events
Weekly update
A roundup of the hottest topics
XNCR
News
- Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago [Yahoo! Finance]Yahoo! Finance
- Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at BMO Capital Markets from $34.00 to $32.00. They now have an "outperform" rating on the stock.MarketBeat
- Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at Raymond James from $58.00 to $40.00. They now have a "strong-buy" rating on the stock.MarketBeat
- Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at Royal Bank of Canada from $32.00 to $31.00. They now have an "outperform" rating on the stock.MarketBeat
- Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock, down previously from $36.00.MarketBeat
XNCR
Earnings
- 5/9/24 - Miss
XNCR
Sec Filings
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- XNCR's page on the SEC website